Deerfield Management Company — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Adela develops blood-based diagnostic tests that analyze cell-free DNA using whole methylome analysis to detect and monitor cancer.
BiotechDigital HealthHealthtechFoster City, US
Daniel Diniz De Carvalho(Executive Officer, Promoter)Scott Bratman(Executive Officer, Director)Anne-Renee Hartman(Founder)Alan Williams(Executive Officer)Lisa Alderson(Executive Officer, Director)Priscilla Huang(Executive Officer)
Board seatAndrew ElBardissi· per SEC Form D
Co-investorsDecheng CapitalF-Prime CapitalOrbiMedMenlo Ventures
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)Gregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesMPM BioImpactRA CapitalDCVC Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.